Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome

American Journal of Health-System Pharmacy

Volumn 65, Issue 15 SUPPL. 7, 2008, Pages

  Dobesh, Paul P ^a,e   Phillips, Katherine W ^b   Haines, Stuart T ^c,d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^d UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Anticoagulants; Bivalirudin; Clopidogrel; Dosage; Drugs; Enoxaparin; Fondaparinux; Heparin; Platelet aggregation inhibitors; Toxicity

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALLOPURINOL; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CREATINE KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MORPHINE; THIENOPYRIDINE DERIVATIVE; TROPONIN;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; BLEEDING; CASE REPORT; CLINICAL PROTOCOL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; GOUT; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SINGLE DRUG DOSE; ST SEGMENT; THROMBOSIS; TREATMENT OUTCOME;

EID: 49549124264     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080242     Document Type: Conference Paper

References (27)

1. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007; 116:e148-304.
2. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics - 2008 update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117: e25-e146.
3. The FRagmin and Fast Revascularisation during Instability in Coronary artery disease Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999; 354:708-15.
4. Wallentin L, Lagerqvist B, Husted S et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease. Lancet. 2000; 356:9-16.
5. Cannon CP, Weintraub WS, Demopoulos LA et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344:1879-87.
6. Cohen M, Demers C, Gurfinkle EP et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447-52.
7. Antman EM, McCabe CH, Gurfinkle EP etal. Enoxaparin prevents deaths and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI 11B) trial. Circulation. 1999; 100:1593-601.
8. Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004; 292:45-54.
9. Mahaffey KW, Cohen M, Garg J et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA. 2005; 294:2594-600.
10. Rao AK, Pratt C, Berke A etal. Thrombolysis in Myocardial Infarction (TIMI) Trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988; 11:1-11.
11. Stone GW, Bertrand M, Colombo A et al. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial; study design and rationale. Am Heart J. 2004; 148:764-75.
12. Stone GW, McLaurin BT, Cox DA et al. Bivalirudin for patients with acute coronary Syndromes. N Engl J Med. 2006; 355:2203-16.
13. Lincoff AM, Bittl JA, Harrington RA et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003; 289:853-63.
14. Yusuf S, Mehta SR, Chrolavicius S et al.; Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464-76.
15. Stone GW, White HD, Ohman EM et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007; 369:907-19.
16. Blazing MA, de Lemos JA, White HD et al.; A to Z Investigators. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin. A randomized controlled trial. JAMA. 2004; 292:55-64.
17. Kastrati A, Mehilli J, Schühlen H et al.; Intracoronary Stenting and Antithrombotic Regimen - Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with Clopidogrel. N Engl J Med. 2004;350:232-8.
18. Mehilli J, Kastrati A, Scḧhlen H et al.; Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation. 2004; 110: 3627-35.
19. Kastrati A, Mehilli J, Neumann FJ et al.; Intracoronary Stenting and Antithrombotic Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006; 295:1531-8.
20. Hamm CW, Heeschen C, Goldmann B et al.; c7E3 FAB Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin I levels. N Engl J Med. 1999; 340:1623-9.
21. 21: Heeschen C, Hamm CW, Goldmann B et al.; PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999; 354:1757-62.
22. Lovenox package insert. Bridgewater, NJ: sanofi-aventis U.S., LLC; 2007 Jun.
23. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502.
24. Mehta SR, Yusuf S, Peters RJ et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358:527-33.
25. Steinhubl SR, Berger PB, Mann JT 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention; a randomized controlled trial. JAMA. 2002;288:2411-20.
26. Hochholzer W, Trenk D, Frundi D et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation. 2005;111:2560-4.
27. Patti G, Colonna G, Pasceri V et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005; 111:2099-106.